Kaplan-Meier survival analysis showed no significant association between LSM2 alterations and patient survival (p=0.375, Figure 4C), suggesting that genetic alterations may not be the primary driver of LSM2’s role in glioma progression. This evidence concerns the gene LSM2 and central nervous system cancer.